Drug Profile


Alternative Names: FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) - SEEK; Influenza virus vaccine (FLU-v) – SEEK; Universal influenza vaccine - SEEK

Latest Information Update: 22 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SEEK
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 25 May 2017 SEEK completes a phase IIb trial in influenza virus infections (In volunteers) in United Kingdom (NCT03180801)
  • 22 Jul 2016 Phase-II clinical trials in Influenza virus infections (In volunteers) in Netherlands (SC) (EudraCT2015-001932-38)
  • 22 Apr 2016 Flu and mosquito-borne disease vaccine platforms licensed to Imutex worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top